Pulse 2.0 reported that Typewriter Therapeutics emerged from stealth with a $56 million Series A. The round was co-led by AN Venture Partners and RA Capital Management, with participation from ANRI, Gemseki and SBI US Gateway Fund. The company stated its focus on developing in vivo CAR T medicines. The announcement supplies the first public details on the startup's financing and therapeutic direction.